ADAM10 and atherosclerosis: The long non-coding RNA (lncRNA), cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), binds to and recruits DNMT1 to the ADAM10 promoter, hypermethylating the promoter and downregulating ADAM10, ultimately reducing the inflammatory response and promoting cholesterol efflux in atherosclerosis [64].